Le consortium microÃ©talage tissulaire de la Fondation cancer du sein du QuÃ©bec pour l'Ã©valuation de biomarqueurs (QBCF-TMAC), Canada

Registration Status: Completed

Objective: Resource de micro-Ã©talage tissulaire provenant de 3 diffÃ©rentes institutions (CHUM, CUSM et CHU de QuÃ©bec). Le QBCF-TMAC comprend sÃ©rie de micro-Ã©talages tissulaires construits Ã partir de tissus (FFPE) provenant de 2000 patientes atteintes du cancer du sein pour lesquelles nous avons des donnÃ©es de suivi clinique. L'objectif est de permettre l'Ã©tude de biobmarqueurs sur une cohort de patientes multi-centrique afin de mieux comprendre la maladie.

Registered Biobank Name	Le consortium microÃ©talage tissulaire de la Fondation cancer du sein du QuÃ©bec pour l'Ã©valuation de biomarqueurs (QBCF-TMAC)
Biobank Leader	Veronique Ouellet
Country	Canada
Email for biobank inquiries	veronique.ouellet.chum@ssss.gouv.qc.ca
Principal Investigator	Anne-Marie Mes-Masson, Caroline Diorio, RÃ©jean Lapointe, Morag Park
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).